Copiktra
FDA Issues Warning on Duvelisib
The FDA is warning that results from a clinical trial show a possible increased risk for death with use of the PI3 ...
JULY 6, 2022
FDA Approves Copiktra for Relapsed or Refractory CLL, SLL
Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of ...
SEPTEMBER 29, 2018
Load more